Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | BAX | Q07812 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15669384 | 0.87 | AKR1C3 (0.51) | SMN1; SMN2PARP10HPGDERCC5FEN1 | |
| SCHEMBL22071794 | 0.87 | MMP13 (0.47) | SMN1; SMN2HPGDMAPK14MEN1KMT2A | |
| SCHEMBL3938851 | 0.86 | ALDH1A1 (0.48) | SMN1; SMN2HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL15670226 | 0.85 | ALDH1A1 (0.43) | SMN1; SMN2HPGDMAPK14MMP1MEN1 | |
| SCHEMBL15613586 | 0.84 | MAOB (0.49) | LTA4HSMN1; SMN2PARP10HPGDMEN1 | |
| SCHEMBL14643731 | 0.84 | NPC1 (0.41) | PARP10HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL15613594 | 0.83 | MAOB (0.50) | SRD5A2MEN1KMT2A | |
| SCHEMBL18173604 | 0.83 | LTA4H (0.46) | LTA4HSMN1; SMN2PARP10HPGDSRD5A2 | |
| SCHEMBL17407842 | 0.80 | LTA4H (0.54) | LTA4HSMN1; SMN2PARP10HPGDSRD5A2 | |
| SCHEMBL2475097 | 0.80 | MAOB (0.54) | SMN1; SMN2PARP10SRD5A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| CN-119504592-A | Synthesis method of 3-amino-5- (4-phenoxyphenyl) -4-cyano-1H-pyrazole | 深圳智微通科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240358707-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240317756-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-20 | — | — | US | disclosed |
| CN-113968842-B | Ibutinib intermediate compound | 鲁南制药集团股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117623982-A | Synthesis method of ibrutinib key intermediate | 南京亿华药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | LTA4H 2846/4885SMN1; SMN2 4780/4885PARP10 1398/4885 |
| US-20240358707-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | LTA4H 1313/4885SMN1; SMN2 4262/4885PARP10 655/4885 |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | LTA4H 1058/4885SMN1; SMN2 4370/4885PARP10 1884/4885 |
| US-20240317756-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885SMN1; SMN2 3147/4885PARP10 591/4885 |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | BTK, CD274, BCL9 | LTA4H 4321/4885SMN1; SMN2 2766/4885PARP10 1883/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | LTA4H 3535/4885SMN1; SMN2 1992/4885PARP10 1089/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | LTA4H 2846/4885SMN1; SMN2 4780/4885PARP10 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.